1. Introduction
Radical cystectomy, pelvic lymph node dissection, and urinary diversion remain the standard of care for patients with muscle-invasive bladder cancer [
1]. Despite substantial improvement over the last decades in terms of surgical technique including robotic-assisted surgery, this procedure is still associated with substantial intraoperative blood loss and transfusion of packed red blood cells (PRBC) with or without administration of fresh frozen plasma (FFP) [
2,
3]. While robotic-assisted radical cystectomy has been associated with reduced blood loss and blood transfusion and is gaining more relevance, open radical cystectomy is still widely performed worldwide [
4]. An overly restrictive blood transfusion strategy has been shown to increase the risk of the composite event “inadequate oxygen supply plus mortality” in a systematic review and meta-analysis, including context-specific conditions like patients’ characteristics and clinical setting [
5]. On the other hand, the reported harm of blood transfusions is manifold. Perioperative blood transfusions have been associated with worse outcomes following cystectomy [
6,
7,
8,
9,
10,
11,
12]. Blood transfusions have an immunomodulatory and immunosuppressive effect in the perioperative period [
13,
14], which predisposes patients to an increased rate of infection [
15,
16]. The intraoperative period is also crucial as the physiological response to surgery can induce a pro-tumor environment and thus negatively impact the control of minimal residual disease or metastatic spread of tumor cells. In this setting, the administration of PRBC and FFP with its profound negative effects on the immune system is detrimental [
17]. In addition, blood transfusions per se are associated with adverse reactions like transfusion-related acute lung injury, which is considered the leading cause of blood transfusion-related morbidity. Finally, blood transfusions result in a relevant increase in overall medical costs [
18,
19].
Cystectomy patients are particularly inclined to receive blood transfusions as a substantial number of patients (up to 50%) are anemic preoperatively [
20,
21]. Based on these findings, we aimed to determine the risk factors for early blood transfusions, to identify potentially modifiable pre- and intraoperative factors, and to develop a nomogram to identify patients in need of preoperative optimization to reduce perioperative blood transfusions in patients planned for cystectomy.
2. Materials and Methods
This study reports a single, tertiary, high case-load center cohort study in accordance with the STROBE recommendations. Ethical approval was provided by the Ethics Committee of Canton Bern, Switzerland (2 June 2016, KEKBE 2016-00660), and the need for informed consent was waived.
2.1. Study Population and Data Collection
We identified 1174 consecutive patients at the Department of Urology, Bern University Hospital, between 4 January 2000 and 13 June 2016. We excluded six (0.51%) patients with insufficient follow-up or incomplete data, leaving 1168 for the final analysis.
All patient data evaluated were from a prospectively maintained database, including all relevant preoperative and oncological variables. Surgical factors were duration of surgery, intraoperative blood loss, previous surgery, perioperative need for PRBC and FFP transfusion, defined as blood transfusion within the first 24 h after the beginning of surgery [
22,
23].
Our institution has performed a similar and standardized open surgical technique for cystectomy and urinary diversion for the last 20 years, which has been described previously according to the Studer’s technique [
24,
25]. All patients were followed prospectively. During the observed period, PRBC was administered if hemoglobin values decreased to <80 g/L (or <100 g/L in patients with coronary artery disease). FFP was administered in the case of clinical coagulopathy or secondary to coagulation factor deficiency.
2.2. Outcome Measures
The need for a blood transfusion cannot be based on absolute blood loss alone but also depends on the patient’s blood volume. We, therefore, decided to implement a blood loss ratio based on the following calculations [
26]:
Indexed blood volume:
Estimated blood volume:
Blood loss ratio:
where BVi = indexed blood volume, BMI = body mass index, BVe = estimated blood volume, BLr = blood loss ratio, BLa = absolute blood loss
2.3. Statistical Analysis
Baseline, intraoperative, and postoperative variables between patients who received blood transfusions and patients who did not were compared. Continuous variables are presented as median and interquartile ranges (IQR) and categorical variables as frequencies (%). Group comparisons were calculated using the χ2 test for categorical and the Wilcoxon test for continuous variables. To identify independent risk factors for blood transfusions, we performed multiple logistic regression analyses. We first partitioned data into a training (90%) and a testing set (10%) to avoid overfitting and to assess model performance (ROC-AUC) on previously unseen data. We performed a stepwise selection procedure minimizing the Akaike information criterion (AIC) using the MASS package for R for the variable section. BMI, Charlson comorbidity index (CCI), use of blood thinners, previous surgery, tumor stage (using polynomial contrasts), positive nodal stage and neoadjuvant chemotherapy, duration of surgery, use of norepinephrine, and the total amount of fluid administered as well as the presence of and all two-way interactions between blood loss ratio, preoperative hemoglobin, age, and gender were evaluated for predictors of transfusion.
All continuous variables were normalized. Multicollinearity between predictors was checked using the variance inflation factor. Marginal means were calculated for ordinal categorical predictors using the “emmeans” package with multiplicity adjustment using the multivariate t distribution method. Model fit was assessed with the le Cessie–van Houwelingen–Copas–Hosmer global goodness of fit test, the Hosmer–Lemeshow test, binned residual plots (“performance” package), and GiViTi calibration plots (“givitiR” package) [
27,
28] (
Appendix A,
Table A1,
Figure A1 and
Figure A2).
A nomogram was used to visualize the final logistic regression model using the “rms” package [
14]. We chose the inverse-logit transformation of the linear predictor to depict the probabilities of the outcomes.
We conducted a sensitivity analysis using modern machine learning models, especially elastic net logistic regression, random forest classification, and support vector machine. The results are depicted in the
Appendix B and
Appendix C (
Table A3 and
Figure A3).
A two-sided p < 0.05 was considered significant. Analyses were performed using the R software environment (R Foundation for Statistical Computing, Vienna, Austria, Version 4.0.2).
The sample size was based on a consecutive series of patients who underwent cystectomy and urinary diversion during the observation time. No formal statistical power calculation was calculated before the study.
3. Results
Overall, 370/1168 patients (31.7%) received blood transfusions within 24 h after the beginning of surgery. In the univariate analysis, patients in the transfused group were older (71 (64–77) vs. 67 years (59–74);
p < 0.001), more often had neoadjuvant chemotherapy (20.3% vs. 12.7%;
p = 0.001), were more often taking oral anticoagulants (5.7% vs. 2.9%;
p = 0.03), had lower preoperative hemoglobin values (120 (104–131) vs. 135 g/L (123–145),
p < 0.001) and were more comorbid (
p < 0.001). There was a higher proportion of women (37.8% vs. 29.9%,
p = 0.009) and more with advanced disease (positive nodal stage (
p = 0.009) and tumor stage (
p < 0.001)) in the transfused group. Duration of surgery was longer in transfused patients (409 (351–454) vs. 390 min (345–426);
p < 0.001), and blood loss was higher (1400 mL (1000–2088) vs. 900 mL (700–1245);
p < 0.001). This last observation persisted when blood loss ratio was applied (0.31 (0.22–0.42) vs. 0.19 (0.14–0.26). Consequently, the amount of crystalloids administered was higher 5.3 mL/kg/h (3.80–7.06) vs. 4.5 mL/kg/h (3.30–6.02);
p < 0.001) in transfused patients (
Table 1).
The multiple logistic regression model is shown in
Figure 1. ROC-AUC assessed on an independent test set was 0.87. The model showed a well-calibrated goodness of fit (Hosmer and Lemeshow C test:
p = 0.617, Hosmer and Lemeshow H test:
p = 0.100 and le Cessie–van Houwelingen–Copas–Hosmer test:
p = 0.525). Diagnostic performance indicators were 65% sensitivity and 91% specificity. Multiple logistic regression detected blood loss ratio (OR: 6.572 (95% CI: 4.878–8.853);
p < 0.001), oral anticoagulants (2.701 (1.163–6.270),
p = 0.021), preoperative hemoglobin (0.316 (0.255–0.391),
p < 0.001), age (1.678 (1.379–2.042),
p < 0.001), and tumor stage (linear trend: 2.067 (1.317–3.244),
p = 0.002 and quadratic trend: 1.623 (1.059–2.489),
p = 0.026) as significant predictors for blood transfusions (
Table 2). The interaction between female sex and blood loss ratio was significant (1.344 (1.011–1.787),
p = 0.042).
Table 3 shows the estimated marginal means for confirmed tumor stage with implemented polynomial contrasts. With more advanced tumor stages, there was a significantly increased risk for blood transfusions: pT3-4 vs. pT0-2 (OR: 2.028 (95% CI: 1.251–3.287),
p = 0.001).
The sensitivity analyses using sophisticated machine learning models showed a non-inferiority of our traditional logistic regression model. We thus favored it because of the better interpretability (
Appendix B and
Appendix C).
4. Discussion
This study aimed to detect predictors for perioperative blood transfusion and to develop a nomogram to predict the need for transfusion in patients undergoing cystectomy. In our cohort, we found an incidence of blood transfusion of around 30%, comparable with the current literature [
29,
30].
Blood loss ratio, preoperative hemoglobin, and advanced age had the strongest association with the likelihood of receiving a blood transfusion. Other relevant factors were the use of oral anticoagulants, advanced tumor stage, and interaction of female sex with blood loss ratio.
Age and tumor stage are given for the perioperative period, but their impact on the probability of a blood transfusion is limited as they contribute to the total score in the nomogram by less than 2 points. This holds true for the use of oral anticoagulants as well.
However, we identified two potentially modifiable factors that highly influence the probability of blood transfusion. These are easily discernable in the developed nomogram by a thick line indicating their predominance: preoperative hemoglobin and blood loss ratio outweigh all other factors by far, as they contribute up to 16 points to the total score in the nomogram.
The leading and most evident protective factor is a high circulating oxygen transport capacity, thus a high preoperative hemoglobin value. Its higher impact compared to other factors like duration of surgery, tumor stage, or oral anticoagulation is striking, particularly for female patients. This further emphasizes the importance of a solid preparation of patients by implementing standardized patient blood management concepts prior to cystectomy. Preoperative anemia should be corrected accordingly, through intravenous administration of an iron formulation, which results in a more rapid response compared to the oral formulation [
31,
32]. In addition, vitamin B12 and folic acid are also recommended for intravenous iron administration [
33].
Furthermore, the use of continuous low-dose norepinephrine intraoperatively was included in the final model and nomogram, albeit not reaching statistical significance. This has been shown previously and is now confirmed in a large series of more than 1000 patients [
34,
35]. The protective effect of norepinephrine against blood transfusion is most likely attributed to vasoconstriction induced by the pre-emptive/concomitant use of a predominantly α-adrenergic vasopressor with only mild but dose-dependent β-adrenergic effects [
29,
35].
Female sex has been associated with an increased rate of blood transfusion in cardiac and major non-cardiac surgery [
36,
37,
38]. Furthermore, Siegrist et al. found in a large cystectomy cohort that blood loss and transfusion rate were higher in 280 females [
39]. In our series, this is only true if interacted with the blood loss ratio, potentially due to the lower circulating blood volume in females. Based on our nomogram, anemic female patients have a nearly twofold higher risk of receiving a blood transfusion than male patients with a similar blood loss ratio. In addition, we confirmed once again that the type of urinary diversion has no impact on blood loss and the rate of blood transfusion [
34].
Although blood transfusions can be lifesaving and necessary in some cases, and they are safer than they have ever been, they still negatively influence the immune system. Blood transfusions are associated with promoting a proangiogenic environment inducing tumor growth by releasing cytokines IL6, IL10, and TNFα, and regulatory T-cell activation suppressing the anti-tumoral Th1 response [
14]. Notably, not only PRBC but also FFP induce a pro-inflammatory burden and have the potential to affect natural killer cell activity. FFP contains Th2 cytokines, which induce a dose-dependent release of TNFα and IL10 [
40]. This cytokine response is known to be pro-tumoral.
The ideal perioperative blood transfusion strategy in major oncological surgery remains unclear. This is especially important for older comorbid patients because a too restrictive blood transfusion regimen could increase the risk of early major postoperative complications (ischemic, cardiogenic). On the other hand, a too liberal strategy raises the risk of thromboembolic events [
5,
41,
42,
43]. Thus, a careful balance between the short-term benefits of blood transfusions in terms of reduction in early major postoperative complications versus the long-term benefits in terms of better cancer-related outcomes should be made depending on the patient's characteristics. Meticulous surgical technique reducing blood loss, restrictive fluid administration avoiding hemodilution, normothermia reducing the risk of coagulopathy, and a restrictive threshold for transfusions of PRBC and FFP are valuable intraoperative options to reduce blood transfusion rates [
29,
44]. In the era of cryoprecipitate and fibrinogen concentrates, the indication for FFP should be reconsidered as it has been associated with transfusion-associated circulatory overload and transfusion-related acute lung injury. Malignancy and the disturbances in the perioperative period are known to induce prothrombotic stimuli, and administration of blood transfusions has been associated with an elevated risk of thromboembolic events [
45]. Hence, the administration of PRBC and FFP units must be evaluated carefully.
The key finding of this study is that the most important and most efficient method to avoid blood transfusion is preoperative patient optimization as depicted in our nomogram. The cornerstone in preparing patients scheduled for cystectomy is to optimize hemoglobin levels in anemic patients to within the normal to high hemoglobin range (≥130 g/L in both sexes) as proposed in the international consensus statement on the perioperative management of anemia and iron deficiency [
46]. Their recommendations include a perioperative care pathway to investigate and correct anemia. In order to minimize the risk of unfavorable transfusion-related outcomes, the implementation of patient blood management strategies is valuable, even if the time between decision and surgery is limited, to avoid postponing major cancer-related surgery [
47].
5. Conclusions
The incidence of perioperative blood transfusions in patients undergoing cystectomy was around 30%. Of the predictors affecting blood transfusions, only blood loss ratio and preoperative hemoglobin can be addressed by meticulous surgery and surgical technique, or optimization of preoperative hemoglobin as depicted in our nomogram. Others, like age or advanced tumor disease, are not modifiable. This emphasizes the importance of optimal preparation of patients undergoing cystectomy and minimal bleeding during surgery. We, therefore, strongly suggest the implementation of solid patient blood management, as previously proposed, to increase preoperative hemoglobin concentration.
Limitations
This is a retrospective study based on prospectively recorded data. We, therefore, cannot exclude deviation of the transfusion protocol due to clinical decision-making. This limits the generalizability of these findings. However, we were able to confirm, in part, precedent results. In addition, there is a high likelihood for a negative selection bias in the group receiving blood transfusions. Patients receiving blood transfusions were more likely to have more advanced oncological disease, were older, and more comorbid at the time of surgery. A randomized, controlled trial, which would be the ideal design to avoid bias and answer this question, seems ethically not justifiable.